Ventilator-associated pneumonia in the ICU
By A. Kalanuria, Wendy Zai, M. Mirski. Critical Care, 2014
616 citations recorded by the source corpus.
Ventilator-associated pneumonia (VAP) is defined as pneumonia that occurs 48–72 hours or thereafter following endotracheal intubation, characterized by the presence of a new or progressive infiltrate, signs of systemic infection (fever, altered white blood cell count), changes in sputum characteristics, and detection of a causative agent [1]. VAP contributes to approximately half of all cases of hospital-acquired pneumonia [1, 2]. VAP is estimated to occur in 9–27 % of all mechanically ventilated patients, with the highest risk being early in the course of hospitalization [1, 3]. It is the second most common nosocomial infection in the intensive care unit (ICU) and the most common in mechanically ventilated patients [4, 5]. VAP rates range from 1.2 to 8.5 per 1,000 ventilator days and are reliant on the definition used for diagnosis [6]. Risk for VAP is greatest during the first 5 days of mechanical ventilation (3 %) with the mean duration between intubation and development of VAP being 3.3 days [1, 7]. This risk declines to 2 %/day between days 5 to 10 of ventilation, and 1 %/day thereafter [1, 8]. Earlier studies placed the attributable mortality for VAP at between 33–50 %, but this rate is variable and relies heavily on the underlying medical illness [1]. Over the years, the attributable risk of death has decreased and is more recently estimated at 9–13 % [9, 10], largely because of implementation of preventive strategies. Approximately 50 % of all antibiotics administered in ICUs are for treatment of VAP [2, 4]. Early onset VAP is defined as pneumonia that occurs within 4 days and this is usually attributed to antibiotic sensitive pathogens whereas late onset VAP is more likely caused by multidrug resistant (MDR) bacteria and emerges after 4 days of intubation [1, 4]. Thus, VAP poses grave implications in endotracheally intubated adult patients in ICUs worldwide and leads to increased adverse outcomes and healthcare costs. Independent risk factors for development of VAP are male sex, admission for trauma and intermediate underlying disease severity, with odds ratios (OR) of 1.58, 1.75 and 1.47–1.70, respectively [7].
Subfields: Clinical Psychology, Critical Care and Intensive Care Medicine, Epidemiology
View Paper: https://www.semanticscholar.org/paper/c057fd1778368837b7ed8e574f1f3d4c1a3b7e2f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Rebekah M. Martin
- M. Tariq
- Shahana Khattak
- Muhammad Ali
- M. Farrukh
- Hina Ahsan
- M. Bachman
- A. Usman
Citations in the corpus
- Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae (2018, background): “Klebsiella species are also a leading cause of ventilator-associated pneumonia (VAP) among patients in intensive care units (ICUs) (Kalanuria et al., 2014; Selina et al., 2014), and VAP is responsible for 83% of hospital-acquired (HA) pneumonias (Richards et al., 2000).”
- Rational use of antibiotics in an intensive care unit: a retrospective study of the impact on clinical outcomes and mortality rate (2019, result): “5%) associated with ventilator since they are most difficult to manage.(27,28) The frequency of ventilatoracquired nosocomial infection in our study was quite similar with previously reported data in Pakistan.”